On April 13, 2022 Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, reported that the company’s Chief Financial Officer, Andreas Emmenegger, and Chief Operating Officer, Michael Stumpp, will participate in the upcoming Kempen Life Sciences investor conference on April 20 & 21, 2022 (Press release, Molecular Partners, APR 13, 2022, View Source [SID1234612163]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation Details:

Kempen Life Sciences Conference – company presentation

Wednesday, April 20, 2022, at 16:30 CET (10:30 AM EDT)
The corporate presentation will be made available through the Molecular Partners website.